The preclinical discovery and development of opicapone for the treatment of Parkinson’s disease

dc.creatorEttcheto M.
dc.creatorBusquets O.
dc.creatorSánchez-Lopez E.
dc.creatorCano A.
dc.creatorManzine P.R.
dc.creatorVerdaguer E.
dc.creatorOlloquequi J.
dc.creatorAuladell C.
dc.creatorFolch J.
dc.creatorCamins A.
dc.date.accessioned2020-09-02T22:17:21Z
dc.date.accessioned2022-11-08T20:19:26Z
dc.date.available2020-09-02T22:17:21Z
dc.date.available2022-11-08T20:19:26Z
dc.date.created2020-09-02T22:17:21Z
dc.date.issued2020
dc.identifier15, 9, 993-1004
dc.identifier17460441
dc.identifierhttps://hdl.handle.net/20.500.12728/4408
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5143172
dc.languageen
dc.publisherTaylor and Francis Ltd
dc.subjectdyskinesia
dc.subjectentacapone
dc.subjectOpicapone
dc.subjectParkinson’s disease
dc.subjecttolcapone
dc.subjectopicapone
dc.subjectArticle
dc.subjectcardiotoxicity
dc.subjectclinical study
dc.subjectconstipation
dc.subjectdizziness
dc.subjectdrug approval
dc.subjectdrug efficacy
dc.subjectdrug half life
dc.subjectdrug marketing
dc.subjectdrug mechanism
dc.subjectdrug research
dc.subjectdrug safety
dc.subjectdrug tolerability
dc.subjectdyskinesia
dc.subjectevaluation study
dc.subjecthuman
dc.subjectinsomnia
dc.subjectliver toxicity
dc.subjectmaximum concentration
dc.subjectmotor performance
dc.subjectnonhuman
dc.subjectParkinson disease
dc.subjectpharmacokinetic parameters
dc.subjectpharmacological parameters
dc.subjectpreclinical study
dc.subjectpriority journal
dc.subjectside effect
dc.subjectsystematic review
dc.subjectxerostomia
dc.titleThe preclinical discovery and development of opicapone for the treatment of Parkinson’s disease
dc.typeArticle


Este ítem pertenece a la siguiente institución